147 related articles for article (PubMed ID: 34115701)
21. MALT Lymphoma in Histologic Transformation: FDG-Avid but Pentixafor-Negative.
Tang R; Chen X; Liu M; Shu Q; Cai L
Clin Nucl Med; 2024 Mar; 49(3):276-277. PubMed ID: 38306380
[TBL] [Abstract][Full Text] [Related]
22. The Value of Targeting CXCR4 With 68Ga-Pentixafor PET/CT for Subtyping Primary Aldosteronism.
Zheng Y; Long T; Peng N; Zhen M; Ye Q; Zhang Z; He Y; Chen Z; Gan Y; Luo M; Li C; Liu Z; Guo M; Wang M; Luo X; Hu S; Liu L; Jiang T
J Clin Endocrinol Metab; 2023 Dec; 109(1):171-182. PubMed ID: 37477496
[TBL] [Abstract][Full Text] [Related]
23. Low rate of spleen involvement in sporadic Burkitt lymphoma at staging on PET-CT.
Davidson T; Priel E; Schiby G; Raskin S; Chikman B; Nissan E; Benjamini O; Nissan J; Goshen E; Ben-Haim S; Salomon O; Avigdor A
Abdom Radiol (NY); 2018 Sep; 43(9):2369-2374. PubMed ID: 29460043
[TBL] [Abstract][Full Text] [Related]
24. 68Ga-Pentixafor PET/MRI for Treatment Response Assessment in Mantle Cell Lymphoma: Comparison Between Changes in Lesion CXCR4 Expression on PET and Lesion Size and Diffusivity on MRI.
Mayerhoefer ME; Raderer M; Weber M; Lamm W; Kiesewetter B; Hacker M; Nics L; Schmitl S; Leithner D; Wester HJ; Haug A
Clin Nucl Med; 2023 Jul; 48(7):557-562. PubMed ID: 37272977
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical detection of chemokine receptor 4 expression in chronic osteomyelitis confirms specific uptake in 68Ga-Pentixafor-PET/CT.
Bouter Y; Meller B; Sahlmann CO; Wolf BJ; Langer L; Bankstahl JP; Wester HJ; Kropf S; Meller J; Bouter C
Nuklearmedizin; 2018 Sep; 57(5):198-203. PubMed ID: 30267402
[TBL] [Abstract][Full Text] [Related]
26. 18F-FDG PET/CT Imaging of Burkitt Lymphoma Presenting With Unusual Muscle Involvement.
Dirlik Serim B; Gurleyen Eren T; Oz Puyan F; Durmus Altun G
Clin Nucl Med; 2016 Aug; 41(8):643-5. PubMed ID: 27124681
[TBL] [Abstract][Full Text] [Related]
27. Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.
Bluemel C; Hahner S; Heinze B; Fassnacht M; Kroiss M; Bley TA; Wester HJ; Kropf S; Lapa C; Schirbel A; Buck AK; Herrmann K
Clin Nucl Med; 2017 Jan; 42(1):e29-e34. PubMed ID: 27819856
[TBL] [Abstract][Full Text] [Related]
28. 18F-FDG PET/CT in Extranodal Burkitt Lymphoma.
Jiménez Granero P; García Gómez FJ; Ruiz Mercado M; Borrego Dorado I
Clin Nucl Med; 2015 Sep; 40(9):748-9. PubMed ID: 26098290
[TBL] [Abstract][Full Text] [Related]
29. Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [
Haug AR; Leisser A; Wadsak W; Mitterhauser M; Pfaff S; Kropf S; Wester HJ; Hacker M; Hartenbach M; Kiesewetter-Wiederkehr B; Raderer M; Mayerhoefer ME
Theranostics; 2019; 9(12):3653-3658. PubMed ID: 31281504
[TBL] [Abstract][Full Text] [Related]
30. Myocardial Uptake of 68Ga-Pentixafor in a Patient With Systemic Amyloidosis.
Pan Q; Luo Y; Cao X; Li J
Clin Nucl Med; 2022 Dec; 47(12):1118-1120. PubMed ID: 36342801
[TBL] [Abstract][Full Text] [Related]
31. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
Albano D; Bosio G; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):87-96. PubMed ID: 30276438
[TBL] [Abstract][Full Text] [Related]
32. Spectrum of FDG PET/CT findings in Burkitt lymphoma.
Zeng W; Lechowicz MJ; Winton E; Cho SM; Galt JR; Halkar R
Clin Nucl Med; 2009 Jun; 34(6):355-8. PubMed ID: 19487844
[TBL] [Abstract][Full Text] [Related]
33. [Hybrid imaging in lymphoma].
Mayerhöfer ME; Haug A
Radiologe; 2020 May; 60(5):376-385. PubMed ID: 32296856
[TBL] [Abstract][Full Text] [Related]
34. [
Watts A; Singh B; Singh H; Bal A; Kaur H; Dhanota N; Arora SK; Mittal BR; Behera D
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1216-1227. PubMed ID: 36482077
[TBL] [Abstract][Full Text] [Related]
35. Reduced splenic uptake on
Kraus S; Klassen P; Kircher M; Dierks A; Habringer S; Gäble A; Kortüm KM; Weinhold N; Ademaj-Kospiri V; Werner RA; Schirbel A; Buck AK; Herhaus P; Wester HJ; Rosenwald A; Weber WA; Einsele H; Keller U; Rasche L; Lapa C
Theranostics; 2022; 12(13):5986-5994. PubMed ID: 35966583
[TBL] [Abstract][Full Text] [Related]
36. 18F-FDG PET/CT metabolic activity assessment in infective and neoplastic diseases: a patient with systemic hydatidosis and concomitant Burkitt lymphoma.
Niccoli Asabella A; Altini C; Pisani AR; Ingravallo G; Rubini G
Clin Nucl Med; 2013 Jul; 38(7):546-9. PubMed ID: 23640218
[TBL] [Abstract][Full Text] [Related]
37. Increased Uptake of 68Ga-Pentixafor in Thymic Rebound After Chemotherapy in a Patient With Multiple Myeloma.
Pan Q; Luo Y; Cao X; Li J
Clin Nucl Med; 2021 Jan; 46(1):90-92. PubMed ID: 33181744
[TBL] [Abstract][Full Text] [Related]
38. 18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features.
Zhou X; Dierks A; Kertels O; Kircher M; Schirbel A; Samnick S; Buck AK; Knorz S; Böckle D; Scheller L; Messerschmidt J; Barakat M; Kortüm KM; Rasche L; Einsele H; Lapa C
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824832
[TBL] [Abstract][Full Text] [Related]
39. Tumor Imaging With 68Ga-DOTA-FAPI-04 PET/CT: Comparison With 18F-FDG PET/CT in 22 Different Cancer Types.
Çermik TF; Ergül N; Yılmaz B; Mercanoğlu G
Clin Nucl Med; 2022 Apr; 47(4):e333-e339. PubMed ID: 35085165
[TBL] [Abstract][Full Text] [Related]
40. [Value of Pretherapeutic
Ding CY; Liu HY; Guo Z; Li TN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):438-443. PubMed ID: 28446289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
